Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060083 | 0.93 | CTSK (0.48) | CTSKCTSLCTSSCTSBMGLL | |
| SCHEMBL12190794 | 0.93 | CTSK (0.48) | CTSKCTSLCTSSCTSBMGLL | |
| SCHEMBL3484242 | 0.93 | CTSK (0.48) | CTSKCTSLCTSSCTSBMGLL | |
| SCHEMBL17365581 | 0.89 | VNN1 (0.46) | CTSKCTSLCTSSCTSBMGLL | |
| SCHEMBL30528465 | 0.89 | VNN1 (0.46) | CTSKCTSLCTSSCTSBMGLL | |
| SCHEMBL15894807 | 0.89 | CTSK (0.45) | CTSKCTSLCTSSCTSBMGLL | |
| SCHEMBL26293714 | 0.89 | CTSK (0.52) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL11982516 | 0.80 | CTSK (0.51) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL1643095 | 0.80 | CTSK (0.51) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL17212301 | 0.80 | CTSK (0.44) | CTSKCTSLCTSSMGLLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | CTSK 2281/4885CTSL 1801/4885CTSS 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.